TPST - Tempest Therapeutics, Inc. Quarterly EPS earnings growth
Tempest Therapeutics generates revenue through the commercialization of TPST-1120 small molecules for the treatment of solid tumors. Quarterly earnings per share (EPS) trends demonstrate current efficiency, with the metric holding around 82.90. The development of targeted therapy in US laboratories relies on partnerships with clinics. The company is currently focused on immune activation within the framework of clinical trials.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_TPST_-_Tempest-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Tempest Therapeutics Corp (TPST): Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/12/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Tempest Therapeutics Corp (TPST)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Debt to Equity Tempest Therapeutics|TPST - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Tempest Therapeutics|TPST - Company Aggregate Indebtedness|Debts to Book Capitalization Tempest Tx|TPST - Long-Term Debt|Company Short-Term Debt Tempest Therapeutics|Quick Liquidity Indicator tempesttx.com
- earnings and valuation multiples information:
TPST - Profit After Payment of Taxes|Future Profit Tempest Therapeutics|TPST - Company Value to Net Income|Projected Price to Earnings Tempest Tx|TPST - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Tempest Tx|TPST - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Tempest Therapeutics|TPST - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months tempesttx.com|TPST - Earnings per share increase in current year|Earnings growth forecast for next year Tempest Therapeutics
General company analysis:Tempest Therapeutics, Inc. - TPST
This metric measures the quarterly dynamics of earnings per share, allowing investors to evaluate business capitalization efficiency through the lens of operating profitability. By analyzing the quarterly EPS growth rate on GURU.Markets, one can see how the inelastic demand for target molecules TPST-1120 in oncology transforms the pricing power of Tempest Therapeutics (TPST) into actual financial results.
Analysis of competing companies
BeiGene (ONC) - Year-over-year earnings per share growth for the last twelve months|Halozyme Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (RevMed) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Corp AAPG|Year-over-year net earnings per share growth for the last 12 months CGON (CG Oncology, Inc.)|Year-over-year earnings per share growth rate for the last twelve months URGN|Quarterly EPS earnings growth BCAX (Bicara Therapeutics)|Personalis Inc (PSNL) - Earnings per share growth in annualized terms for the last twelve months|ERAS - Year-over-year earnings per share growth for the last twelve months|Delcath Corp (DCTH) - Year-over-year net earnings per share growth for the last 12 months|Y-mAbs Therapeutics (YMAB) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months AURA (aurabiosciences.com)|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Accuray Inc ARAY|Year-over-year earnings per share growth for the last twelve months SELLAS Life Sciences (SLS)|Year-over-year net earnings per share change for the last twelve months Actuate Therapeutics Inc|Citius Oncology, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months HURA (TuHURA Biosciences Inc.)|TARA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FATE (Fate Therapeutics Inc)|WHWK (aadibio.com) - Year-over-year net earnings per share growth for the last 12 months|TCRX: Year-over-year earnings per share growth rate for the last twelve months|CSBR (Champions Oncology Inc) - Quarterly EPS earnings growth|XBIT: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CVM|OSTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Radiopharm Theranostics RADX|Year-over-year earnings per one share growth for the last 12 months ARTV|Adlai Nortye Limited - Quarterly EPS earnings growth|VERU - Quarterly EPS earnings growth|xiliotx.com (XLO) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months RENB (Renovaro)|MURA (Mural Oncology PLC) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kairos Pharma Inc KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth w2.cytomed.sg (GDTC)|Curis - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months APLM (Apollomics Inc.)|Tharimmune Corp - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Advanced Biomed Inc ADVB|GNPX: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Calidi Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last twelve months Sunshine Biopharma|Xenetic Bio (XBIO) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months SLRX (Salarius)|Year-over-year earnings per share growth rate for the last twelve months PPBT|Year-over-year earnings per share growth for the last twelve months American Oncology Network, Inc. AONC|BGNE (beigene.com) - Year-over-year net earnings per share trend for the last twelve months|CKPT - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Elevation Oncology Inc. ELEV|ICAD (icadmed.com) - Year-over-year net earnings per share growth for the last 12 months|IKNA: Year-over-year earnings per share growth rate for the last twelve months|NTBL (Notable Labs, Ltd.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta (VIRX)|Quarterly EPS earnings growth MOR|Quarterly EPS earnings growth NAYA Biosciences Inc (NAYA)|Year-over-year earnings per share growth for the last twelve months Ascentage Pharma Group Ltd AAPGV
